Randomized trial reveals a complex molecular landscape in gastrointestinal stromal tumors, indicating a need for genetic profiling in clinical management.
Key Points
The aim is to explore the molecular landscape of gastrointestinal stromal tumors (GIST) through a multi-omic approach in a large cohort.
Conducted a multi-omic analysis including targeted panel, whole exome sequencing, and whole transcriptomics on 1,427 GIST cases.
Performed pathological review on KIT/PDGFRA-wild type cases and correlated molecular findings with clinical data and insurance outcomes.
Used next-generation sequencing technologies to identify genetic alterations in GIST subgroups.
Identified three GIST molecular subgroups: KIT-mutant, PDGFRA-mutant, and KIT/PDGFRA-wild-type, each with distinct genetic profiles.
Found that novel somatic copy number alterations may be crucial for GIST progression, beyond known mutations.
Demonstrated that comprehensive genetic profiling can enhance clinical management of GIST.